Tag Archives: Array Biopharma

← Older posts

NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep

The first drug for neurofibromatosis type 1 (NF1) is available to patients following the FDA’s approval of the AstraZeneca treatment earlier this year. Biotech startup NFlection Therapeutics is vying to be runner-up, but its founders say they can eventually win out with a drug that takes a different approach than the commercialized pill while also […]

Posted in Boulder/Denver blog main, Europe blog main, National blog main, Philadelphia, Philadelphia Blog Main, Philadelphia Top stories | Tagged , , , , , , , , , , , , , , , , , | Comments Off on NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep

AstraZeneca Wins First FDA Drug Nod for NF1, a Rare Genetic Disorder

An AstraZeneca drug designed to block tumor growth is now approved as a treatment for neurofibromatosis type 1 (NF1), a rare inherited disorder that leads to tumors on nerves throughout the body. The FDA’s Friday decision for the drug, selumetinib (Koselugo), makes it the first approved treatment for NF1. It’s also the latest twist in […]

Posted in Boulder/Denver blog main, Boulder/Denver top stories, National, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , | Comments Off on AstraZeneca Wins First FDA Drug Nod for NF1, a Rare Genetic Disorder

ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

The European Society for Medical Oncology meeting has wrapped up in Barcelona, the last major clinical cancer conference until December’s annual ASH meeting for blood diseases. We’ve highlighted a few top stories for you. Amid all the fuss over cell, gene, and immunotherapies these days, an old-fashioned small-molecule class of drug called PARP inhibitors have […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More

Upjohn & Mylan to Merge, Freeing Pfizer to Focus on Biopharma R&D

Pfizer became the world’s biggest drug maker by revenue through acquisitions that diversified its portfolio. Now it’s spinning out its off-patent drug division and charting a different course for the remaining company as a smaller business focused on developing innovative new drugs. On Monday, Pfizer (NYSE: PFE) announced that its Upjohn division, which sells drugs […]

Posted in National blog main, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , | Comments Off on Upjohn & Mylan to Merge, Freeing Pfizer to Focus on Biopharma R&D

Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More

[Corrected 6/24/19, 12:08 p.m. See below.] Cancer remains one of the hottest areas for pharma deals and this week saw a big one: Pfizer’s proposed $11.4 billion buyout of Array Biopharma. The announcement comes less than a month after Boulder, CO-based Array announced positive data from a pivotal study of its combination drug in colorectal […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Array Bio Acquired, IPO Spree, Sanofi’s Job Cuts & More

Colorectal Cancer Data Spurs Pfizer to Pay $11.4B for Array Bio

[Updated 11:02 a.m. See below.] Array BioPharma touted data less than a month ago that could shift the treatment landscape for some patients with metastatic colorectal cancer. The data caught the eye of Pfizer, which just agreed this morning to buy the Boulder, CO, cancer drug maker for $11.4 billion. Pfizer (NYSE: PFE) will pay […]

Posted in Boulder/Denver, Boulder/Denver blog main, Boulder/Denver top stories, Indiana blog main, National blog main, National top stories, New York blog main, New York top stories, San Francisco blog main, Seattle blog main | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on Colorectal Cancer Data Spurs Pfizer to Pay $11.4B for Array Bio

Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On

If you’re running a privately held biotech, the time to go public is now. Clinical data already in hand or not, biotechs have charged to Wall Street at a record pace over the past two weeks, raising more than $1 billion in offerings that all met or exceeded their projected valuations. And there are no […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: Big Bucks For Calico, Data Dumps & The IPO Wave Rolls On

Roche-Exelixis Study Fails as Mixed Year Continues For Cancer Drug Combos

This year is a big one for cancer drug combinations, and the results, so far, have been mixed. Some combinations have shown they may change how certain cancers are treated. Others are falling flat in clinical testing. The latest to come up short is a regimen of Roche/Genentech and Exelixis cancer drugs that failed a […]

Posted in Boulder/Denver blog main, Boulder/Denver top stories, Indiana blog main, National blog main, National top stories, New York blog main, New York top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Roche-Exelixis Study Fails as Mixed Year Continues For Cancer Drug Combos

Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks

We’ll start this week’s roundup with several stories from Washington, DC, that could have a lasting effect on public health. The FDA continued its campaign against cigarettes, while the Centers for Medicare & Medicaid Services (CMS) gave a much-needed boost to the developers of cancer diagnostics. In its omnibus spending bill, Congress set aside more […]

Posted in Boston blog main, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: CMS Backs Cancer Tests, Right to Try Passes, AbbVie Sinks

Bio Buyout Spree Continues as SeaGen Bets $614M on Cascadian Cancer Drug

In the latest in a recent spate of biopharma buyouts, Seattle Genetics has struck a deal to acquire Cascadian Therapeutics, gambling on an experimental breast cancer drug in late-stage testing. SeaGen (NASDAQ: SGEN), of Bothell, WA, will pay $10 per share in cash, or $614 million, for Seattle’s Cascadian (NASDAQ: CASC) and its lead drug […]

Posted in Boulder/Denver blog main, National blog main, Seattle, Seattle blog main, Seattle top stories | Tagged , , , , , , , , , , , , , , , , | Comments Off on Bio Buyout Spree Continues as SeaGen Bets $614M on Cascadian Cancer Drug← Older posts